<DOC>
	<DOCNO>NCT01055483</DOCNO>
	<brief_summary>The study determine maximal tolerate dose ( MTD ) panobinostat administer combination fix combination cytarabine ( ara-C ) mitoxantrone adult patient relapse refractory acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>A Phase Ib , Open-label , Multi-center Dose-finding Study Oral Panobinostat ( LBH589 ) Combination With Ara-C Mitoxantrone Salvage Therapy Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Patients cytopathologically confirm diagnosis AML accord WHO criterion , exclude acute promyelocytic leukemia . First relapse AML Primary refractory AML define failure respond initial induction chemotherapy ( CR ) recurrence within 6 month initial CR . Age 18 year ECOG performance status &lt; 2 Prior treatment deacetylase inhibitor Concurrent therapy investigational agent Patients receive cumulative dos ( equivalent anthracyclines ) 360 mg/m2 doxorubicin exclude study . Clinical symptom suggest CNS leukemia LVEF 45 % Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>relapse acute myeloid leukemia</keyword>
	<keyword>refractory acute myeloid leukemia</keyword>
</DOC>